Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients

G. Cannella, G. La Canna, M. Sandrini, M. Gaggiotti, G. Nordio, E. Movilli, S. Mombelloni, O. Visioli, R. Maiorca

Research output: Contribution to journalArticlepeer-review

Abstract

To clarify the role of chronic anaemia in the pathogenesis of the left ventricular hypertrophy (LVH) of chronic uraemia, nine normotensive dialysed patients were studied before and 3 and 6 months after start of intravenous treatment with recombinant human erythropoietin (rHuEpo). M-Mode echocardiographic estimations of left ventricular mass indices (LVMi) and plasma noradrenaline determinations were made at 3 and 6 months, and total blood volume (TBV) only at 6 months. Resting haemoglobin values were 5.9±1.3 (SD) g/dl, increased within 3 months to 10.2±1.2 (P2 body surface area (b.s.a.) and decreased significantly (P

Original languageEnglish
Pages (from-to)31-37
Number of pages7
JournalNephrology Dialysis Transplantation
Volume6
Issue number1
Publication statusPublished - 1991

Keywords

  • Chronic anaemia
  • Chronic uraemia
  • Left ventricular hypertrophy
  • Recombinant human erythropoietin

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Fingerprint Dive into the research topics of 'Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients'. Together they form a unique fingerprint.

Cite this